A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumours or Leukaemia.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2016
At a glance
- Drugs MK 2206 (Primary)
- Indications CNS cancer; Leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- 01 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 May 2012 Planned end date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 03 Apr 2012 Additional lead trial centre and investigator identified as reported by Oregon Health and Science University Institutional Review Board.